 |
 |
 |
| |
De: PR Newswire
Brasil
Para: THERESA CATHARINA DE GÓES CAMPOS
Assunto: Boston Scientific Completes Combination
With Guidant
21 de abril de 2006 15:56 HORALOCAL
Boston Scientific Completes Combination With
Guidant
NATICK, Mass., April 21 /PRNewswire/ -- Boston
Scientific
Corporation (NYSE: BSX) today announced that it
has completed its
combination with Guidant Corporation (NYSE: GDT),
creating a global
leader in cardiovascular devices and one of the
largest medical
technology companies in the world.
In a related transaction before the closing of
the Boston
Scientific-Guidant transaction, Guidant and
Abbott closed the
acquisition by Abbott of Guidant's vascular
intervention and
endovascular businesses.
"This is a momentous day for the employees and
stockholders of the
new Boston Scientific, as well as for thousands
of physicians and
millions of patients around the world," said
Pete Nicholas, Chairman
of Boston Scientific. "As we begin this new
chapter in Boston
Scientific's history, we are committed to
building on our long,
mutual tradition of technological innovation
that helps physicians
provide life-saving treatments to their patients.
We are also
committed to maintaining a culture that values
initiative, creativity
and collaboration -- and that recognizes the
talents and
contributions of people who make a difference
for our company and our
customers."
"We are looking forward to realizing the
substantial benefits of
combining Boston Scientific and Guidant," said
Jim Tobin, President
and Chief Executive Officer of Boston Scientific.
"The new Boston
Scientific will be a broadly diversified medical
technology company
that we believe will command a market valuation
closer to our peers
and generate significant upside potential for
our stockholders. We
are confident the integration will proceed
smoothly, and we extend a
warm welcome to the Guidant employees who are
joining us. I know that
together we can and we will build a successful
future."
Effective as of the close of trading today,
trading in Guidant's
common stock will cease.
Guidant shareholders should expect to receive
information in the
coming weeks regarding the exchange of their
Guidant common stock.
Boston Scientific is a worldwide developer,
manufacturer and marketer
of medical devices whose products are used in a
broad range of
interventional medical specialties. For more
information, please
visit: http://www.bostonscientific.com .
Forward Looking Statements
This press release contains forward-looking
statements, which are
identified by words such as "anticipates," "believes,"
"estimates,"
"expects," "intends," "may," "projects," "plans,"
"will" and similar
expressions intended to identify forward-looking
statements. These
forward-looking statements are subject to risks
and uncertainties
that may cause actual results to differ
materially, including risk
factors relating to our industry as detailed
from time to time in
each of Boston Scientific's and Guidant's
reports filed with the
Securities and Exchange Commission, including
each such company's
most recent Annual Report on Form 10-K. You
should not place undue
reliance on these forward-looking statements,
which speak only as of
the date of this press release. Unless legally
required, Boston
Scientific undertakes no obligation to update
publicly any
forward-looking statements herein, whether as a
result of new
information, future events or otherwise.
SOURCE Boston Scientific Corporation
04/21/2006
CONTACT: Geraldine Varoqui, Boston Scientific PR
Manager
International, +49-2102-489-461, or varoquig@bsci.com,
or Maren
Koban, BSC press office, +44-207-973-4497, or
Mobile, +44-7713-631514,
or mkoban@hillandknowlton.com
Web site: http://www.bostonscientific.com
(BSX GDT)
BNED: NG
FONTE: PR NEWSWIRE LATIN AMERICA
CORAL GABLES - MIAMI-US
CONTATOS: USA-MARY D'LEON
BRASIL-NÉLIA GARCIA
TELS: USA:1-305-507-2550/BRASIL:55-21-2132-8461
FAXES: USA:1-305-461-8670/BRASIL:55-21-2132-8469
E-MAILS: nelia_garcia@prnewswire.com.br
mary_dleon@prnewswire.com
PALAVRA-CHAVE: RJ
PALAVRA-CHAVE/RAMO DE ATIVIDADE: DIVERSOS
PALAVRA-CHAVE/EMPRESA: BOSTON SCIENTIFIC
CORPORATION
O texto acima, distribuído pela PR Newswire
Brasil, é de inteira
responsabilidade de seu cliente. A utilização
deste material não
implica em custo.
|
|
|
|
